| 20.69 0.09 (0.44%) | 04-02 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.63 |
1-year : | 28.77 |
| Resists | First : | 21.09 |
Second : | 24.63 |
| Pivot price | 18.52 |
|||
| Supports | First : | 18.28 |
Second : | 16.54 |
| MAs | MA(5) : | 19.09 |
MA(20) : | 18.47 |
| MA(100) : | 15.3 |
MA(250) : | 11.42 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 85.1 |
D(3) : | 60.7 |
| RSI | RSI(14): 66 |
|||
| 52-week | High : | 21.09 | Low : | 4.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNMD ] has closed It is unclear right now based on current values. 43.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.13 - 21.21 | 21.21 - 21.3 |
| Low: | 19.75 - 19.83 | 19.83 - 19.92 |
| Close: | 20.55 - 20.7 | 20.7 - 20.85 |
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
Fri, 27 Feb 2026
Mind Medicine Inc. (MNMD) Stock Analysis: Exploring Potential Upside in a Transformative Biotech - DirectorsTalk Interviews
Fri, 16 Jan 2026
Mind Medicine (MNMD) Stock Analysis: A Biotech Bet With 90.86% Potential Upside - DirectorsTalk Interviews
Fri, 16 Jan 2026
MindMed stock soars 73% after InvestingPro’s undervalued call in May 2024 By Investing.com - Investing.com
Thu, 15 Jan 2026
MindMed (MNMD) Options Delisting on January 15th - GuruFocus
Mon, 29 Dec 2025
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 41.6 (%) |
| Shares Short | 15,050 (K) |
| Shares Short P.Month | 12,350 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -85.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -10.45 |
| PEG Ratio | 0 |
| Price to Book value | 12.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|